Significant Visual Improvement Reported in Patients with Retinitis Pigmentosa in a cell therapy clinical trial

(c) ReNeuron

ReNeuron Group plc, a UK-based company focused on development of cell-based therapeutics, has announced encouraging results from an early stage trial of its cell therapy for retinitis pigmentosa (RP), which, if approved, could be a competitor to Spark/Novartis’s Luxturna (voretigene neparvovec). Unlike the already-approved gene therapy Luxturna, ReNeuron’s cell-based therapy would not be limited to patients with a disease caused by a certain mutation.